Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Completed

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2016-06-17

Last Posted Date: 2019-09-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 209

Registration Number: NCT02803580

Locations: 🇮🇹
Osp. S. Giuseppe Fatebenefratelli, Milano, Italy
🇮🇹
Azienda Ospedaliera Policlinico di Modena, Modena, Italy
🇮🇹
Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli, Forli, Italy

and more 15 locations

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2016-06-16

Last Posted Date: 2019-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT02802345

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
🇫🇷
HOP Bichat, Paris, France
🇮🇳
Care Institute Of Medical Sciences, Ahmedabad, India

and more 82 locations

Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients

Withdrawn

Conditions: Hemorrhage

Interventions: Drug: idarucizumab

First Posted Date: 2016-06-14

Last Posted Date: 2021-11-18

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02798107

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BI 425809 dose 1
Drug: BI 425809 dose 2
Drug: BI 425809 dose 3
Drug: BI 425809 dose 4
Drug: Placebo

First Posted Date: 2016-06-02

Last Posted Date: 2020-11-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 611

Registration Number: NCT02788513

Locations: 🇬🇧
Fulbourn Hospital, Cambridge, United Kingdom
🇨🇦
Diex Recherche, Sherbrooke, Quebec, Canada
🇦🇹
LKH-Univ. Hospital Graz, Graz, Austria

and more 90 locations

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Phase 4

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: placebo
Drug: nintedanib

First Posted Date: 2016-06-02

Last Posted Date: 2023-12-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 347

Registration Number: NCT02788474

Locations: 🇨🇿
University Hospital Plzen, Plzen-Bory, Plzen, Czechia
🇧🇪
Edegem - UNIV UZ Antwerpen, Edegem, Belgium
🇯🇵
Kindai University Hospital, Osaka, Osakasayama, Japan

and more 83 locations

Anticoagulants Comparative Benefit-risk Ratio in Real Life

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2016-05-27

Last Posted Date: 2018-11-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103101

Registration Number: NCT02785354

Locations: 🇫🇷
1160.263.1 Boehringer Ingelheim Investigational Site, Multiple Locations, France

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Digoxin
Drug: BI 425809
Drug: Warfarin
Drug: Omeprazole

First Posted Date: 2016-05-26

Last Posted Date: 2016-05-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02783040

Locations: 🇩🇪
1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin

First Posted Date: 2016-05-25

Last Posted Date: 2016-05-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02782624

Locations: 🇩🇪
1276.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy

Phase 2

Completed

Conditions: Urologic Neoplasms

Interventions: Drug: Afatinib

First Posted Date: 2016-05-23

Last Posted Date: 2020-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT02780687

Locations: 🇮🇹
A.O. San Camillo Forlanini, Roma, Italy
🇫🇷
HOP Foch, Suresnes, France
🇫🇷
INS Bergonié, Bordeaux, France

and more 27 locations

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Nintedanib
Drug: Capecitabine

First Posted Date: 2016-05-23

Last Posted Date: 2025-02-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1

Registration Number: NCT02780700

Locations: 🇺🇸
Fort Wayne Medical Oncology Hematology, Fort Wayne, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy